Find a Doctor

Dr. Rashmi K Chugh

Regents Of The University Of Michigan
Oncology, Hematology, Internal Medicine
Female
Practicing approx. 23 years

Bio


Rashmi Chugh is an Oncologist and an Internal Medicine specialist in Ann Arbor, Michigan. Dr. Chugh is highly experienced in treating patients with Rhabdoid Tumor Predisposition Syndrome. She has been an author on 79 peer reviewed articles and participated in 181 clinical trials in the past 15 years. She is licensed to treat patients in MI.

Contact

1500 E Medical Center Dr
Ann Arbor, MI 48109, US

Latest Advances


  • Condition: Epithelioid Sarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Tazemetostat
  • Number of Patients: 62
  • Published —
This study evaluated the safety and effectiveness of Tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma.
  • Condition: Primary Cardiac Sarcoma
  • Journal: Expert review of anticancer therapy
  • Treatment Used: Neoadjuvant Chemotherapy with Surgical Resection
  • Number of Patients: 0
  • Published —
The study researched the outcomes of neoadjuvant chemotherapy with surgical resection in patients with primary cardiac sarcoma.
  • Condition: Wild-Type Gastrointestinal Stromal Tumors
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Linsitinib
  • Number of Patients: 20
  • Published —
In this study, researchers evaluated the safety and effectiveness of linsitinib for the treatment of wild type gastrointestinal stromal tumors.
  • Condition: Metastatic Soft-Tissue Sarcoma
  • Journal: Cancer
  • Treatment Used: Gemcitabine, Docetaxel, and Ontuxizumab
  • Number of Patients: 209
  • Published —
This study tested the safety and efficacy of using a combination gemcitabine, docetaxel, and ontuxizumab chemotherapy to treat patients with metastatic soft-tissue sarcoma.
  • Condition: Previously Treated Solid Tumors
  • Journal: Investigational new drugs
  • Treatment Used: Navicixizumab
  • Number of Patients: 66
  • Published —
In this study, researchers evaluated the safety and effectiveness of navicixizumab for the treatment of previously treated solid tumors.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 53
  • Start Date: March 17, 2020
Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 250
  • Start Date: December 22, 2015
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Clinical Trial
  • Status: Completed
  • Phase: Phase 1
  • Intervention Type: Drug, Other, Biological
  • Participants: 30
  • Start Date: June 2008
A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
Clinical Trial
  • Status: Completed
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 36
  • Start Date: June 2005
Phase II Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas

All Publications
View All


  • Sponsor: Society for ImmunoTherapy of Cancer (SITC)
  • Event Name: Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2020
  • Published —
A MULTICENTER PHASE II TRIAL (SWOG S1609, COHORT 51) OF IPILIMUMAB AND NIVOLUMAB IN METASTATIC OR UNRESECTABLE ANGIOSARCOMA: A SUBSTUDY OF DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS (DART)

Contact

1500 E Medical Center Dr
Ann Arbor, MI 48109, US

Affiliations

  • University Of Michigan Health System

Credentials

  • Graduate InstitutionWashington University School Of Medicine
    1998
  • Licenses
    Internal Medicine in MI
  • Board Certifications
    Medical Oncology
    Hematology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.